Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

EnalaprilvsAngiotensin (1-7)

The blood pressure champion that helped millions breathe easier and live longer

The heart-friendly peptide that balances your blood pressure and protects your cardiovascular system

Healing & RecoveryHealing & Recovery

At a Glance

Quick
comparison

Dose Range

Enalapril

2.5 mg–40 mg mg

Angiotensin (1-7)

0.5-1 mcg/kg–5-10 mcg/kg mcg

Frequency

Enalapril

Once daily

Angiotensin (1-7)

Once daily

Administration

Enalapril

Oral tablet

Angiotensin (1-7)

As directed by healthcare provider

Cycle Length

Enalapril

Ongoing/indefinite

Angiotensin (1-7)

Ongoing/indefinite

Onset Speed

Enalapril

Moderate (1-2 weeks)

Angiotensin (1-7)

Moderate (1-2 weeks)

Evidence Level

Enalapril

Strong human trials (Phase 3 or FDA approved)

Angiotensin (1-7)

Moderate human trials (Phase 1-2)

Efficacy

Benefit
ratings

Enalapril
Angiotensin (1-7)

Cardiovascular Health

Enalapril95%
Angiotensin (1-7)0%

Long-term Protection

Enalapril88%
Angiotensin (1-7)0%

Quality of Life

Enalapril82%
Angiotensin (1-7)0%

Heart Health & Protection

Enalapril0%
Angiotensin (1-7)82%

Blood Pressure Balance

Enalapril0%
Angiotensin (1-7)78%

Anti-Inflammatory Support

Enalapril0%
Angiotensin (1-7)74%

Technical Data

Compound
specifications

Enalapril

Molecular Formula

C20H28N2O5

Molecular Weight

376.4 g/mol

Half-Life

Enalapril: 1 hour; Enalaprilat (active form): 11 hours effective half-life

Bioavailability

Approximately 60% oral bioavailability when taken by mouth

CAS Number

75847-73-3

Angiotensin (1-7)

Molecular Formula

C41H62N12O11

Molecular Weight

899.02 g/mol

Half-Life

Approximately 2-6 hours (varies by route of administration)

Bioavailability

Varies by route of administration

CAS Number

25016-41-7

Applications

Best
suited for

Enalapril

Managing hypertension to prevent serious complications

Enalapril is particularly well-suited for individuals focused on managing hypertension to prevent serious complications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Treating heart failure and improving survival rates

Enalapril is particularly well-suited for individuals focused on treating heart failure and improving survival rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Protecting organs from damage caused by high blood pressure

Enalapril is particularly well-suited for individuals focused on protecting organs from damage caused by high blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Angiotensin (1-7)

Cardiovascular health and heart protection

Angiotensin (1-7) is particularly well-suited for individuals focused on cardiovascular health and heart protection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Blood pressure management and hypertension

Angiotensin (1-7) is particularly well-suited for individuals focused on blood pressure management and hypertension. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Recovery from heart-related conditions

Angiotensin (1-7) is particularly well-suited for individuals focused on recovery from heart-related conditions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Anti-inflammatory support

Angiotensin (1-7) is particularly well-suited for individuals focused on anti-inflammatory support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Side
effects

Enalapril

Common

  • Dry cough
  • Dizziness
  • Fatigue
  • Hyperkalemia
  • Angioedema

Serious

  • Severe allergic reaction

Angiotensin (1-7)

Common

  • Hypotension (Low Blood Pressure)
  • Dizziness or Lightheadedness
  • Injection Site Reactions
  • Headache

Serious

  • Hyperkalemia (High Potassium)

Research Status

Safety
& evidence

Enalapril

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Enalapril is an FDA-approved ACE inhibitor with safety data spanning over 40 years of clinical use and post-market surveillance in millions of hypertensive patients. Persistent dry cough occurs in 10-20% of patients, caused by kinase II inhibition and bradykinin accumulation. Hyperkalemia is a serious risk, particularly in renal impairment, diabetes, or concurrent NSAID/potassium-sparing diuretic use—potassium monitoring is essential. Angioedema (0.1-0.2%) is a rare but life-threatening emergency, absolute contraindication for future ACE inhibitor use. Hypotension can occur in volume-depleted patients or those on concurrent vasodilators. Acute kidney injury risk exists in patients with bilateral renal artery stenosis or single kidney. Fetal teratogenicity is well-documented in pregnancy.

Contraindications

  • xPregnancy (causes serious fetal harm)
  • xHistory of angioedema with ACE inhibitors
  • xSevere renal dysfunction
  • xConcurrent use with certain other blood pressure medications
  • xPotassium supplementation without medical supervision

Angiotensin (1-7)

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Angiotensin (1-7) is not FDA-approved and has no completed human clinical trials, with all safety data limited to animal studies and in vitro mechanistic work. Animal studies suggest potential benefits in hypertension and cardiac remodeling but also reveal risks of hypotension, particularly with concurrent ACE inhibitor or ARB therapy. The peptide's effects on systemic inflammation and immune function in animal models are not validated in humans. No pharmacokinetic data exists defining safe doses, optimal delivery routes, or organ accumulation patterns in humans.

Contraindications

  • xSevere hypotension or uncontrolled low blood pressure
  • xAcute myocardial infarction in early stages
  • xConcurrent use with certain ACE inhibitors without medical supervision
  • xPregnancy and breastfeeding (insufficient safety data)

Decision Guide

Which is
right for you?

Choose Enalapril if...

  • Managing hypertension to prevent serious complications
  • Treating heart failure and improving survival rates
  • Protecting organs from damage caused by high blood pressure

Choose Angiotensin (1-7) if...

  • Cardiovascular health and heart protection
  • Blood pressure management and hypertension
  • Recovery from heart-related conditions
  • Anti-inflammatory support
Enalapril vs Angiotensin (1-7) — Peptide Comparison | Peptide Initiative